Myelofibrosis Treatment Algorithm 2018
نویسندگان
چکیده
منابع مشابه
Treatment considerations for primary myelofibrosis.
j u l y/ a u g u s t 2 0 1 0 , v o l . 6 8 , n o 7 / 8 Primary myelofibrosis (PMF) belongs to the group of Philadelphia chromosome negative (Ph) chronic myeloproliferative neoplasms caused by a clonal stem cell disorder presenting with myeloproliferation and fibrosis. The clinical presentation is characterised by anaemia, marked hepatosplenomegaly, leuko-erythroblastosis, constitutional symptom...
متن کاملThe evolving treatment paradigm in myelofibrosis
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV). Average survival of a patient with MF is 5-7 years. Disease complications include fatigue, early satiety, pruritus, painful splenic infarcts, infections and leukemic transformation. Allogeneic hematopoietic stem cell transplant (HSCT...
متن کاملThe surgical paliative treatment of myelofibrosis
The myelofibrosis is a chronic myeloproliferative disease, as the essential trombocitemia and polycythemia vera, described in literature for the first time by Heuck in 1879 1, characterized by the release of circulating immature myeloid precursors that tend to accumulate in the reticuloendotheliale system 2,3. This process, called extramedullary haemopoiesis, leads to secondary complications, s...
متن کاملTreatment of Myelofibrosis: Old and New Strategies
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact o...
متن کاملBiology and treatment of primary myelofibrosis.
Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder associated with an average survival of less than 5 years. Therapy for PMF has used chemotherapeutic agents, immunomodulatory drugs, or biological-response modifiers that have not always been directed at the biological processes that underlie the origins of PMF. Such strategies are palliative and have an uncertain effect on sur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Cancer Journal
سال: 2018
ISSN: 2044-5385
DOI: 10.1038/s41408-018-0109-0